GenScript Biotech Corporation Launches FLASH Gene Service: The Fastest and Most Affordable Gene Synthesis Solution on the Market

PISCATAWAY, N.J., June 18, 2024 /PRNewswire/ -- GenScript Biotech Corporation, renowned for its relentless innovation in synthetic biology and industry-leading gene synthesis services, is excited to announce the launch of its newest offering, GenScript FLASH Gene service, the ultra-fast sequence-to-plasmid (S2P) service. This flagship offering addresses the urgent demand for delivering gene constructs with unmatched speed, quality, and cost-efficiency.

With GenScript's FLASH Gene service, the delivery time from sequence to plasmid construct is just four business days, making it the fastest S2P service in the industry. This groundbreaking service features a flat-rate pricing model starting at just $89, covering gene synthesis, cloning, and plasmid preparation. This advancement is poised to significantly facilitate and accelerate research and discovery efforts in the development of antibody drugs, vaccines, and gene and cell therapies.

Continuing GenScript's commitment to the highest standards of quality and reliability, GenScript's FLASH Gene service guarantees plasmid yield and 100% sequence accuracy. This assurance empowers scientists to focus entirely on their research with complete confidence.

GenScript's FLASH Gene services will be offered from our newly expanded facility in Piscataway, New Jersey, where we delivered our first gene 22 years ago. We are also making this service available to customers across the globe, ensuring the same competitive pricing and rapid turnaround times at all locations.

"We recognize the current market challenges and understand the critical need to develop the FLASH Gene service to support our customers in accelerating breakthroughs," said Ray Chen, Ph.D., President of the Life Science Group at GenScript. "As the pioneer and leader in gene synthesis, we are committed to delivering genes to researchers worldwide in the fastest, most reliable, and efficient manner. Our team has put extensive efforts into platform upgrades, automation, and process optimization, enabling us to offer the groundbreaking FLASH Gene service, the fastest and most cost-effective gene synthesis service. It is our mission to continuously understand the evolving needs of our customers, drawing insights from their feedback and experiences. This commitment drives us to constantly refine our technologies and processes, ensuring that we not only meet but exceed the expectations of the researchers we serve. We are truly grateful for the opportunity to contribute to the ongoing advancements in scientific research."

For more information, visit FLASH Gene Service or contact our customer support team.

About GenScript

GenScript Biotech Corporation (HK.1548) is a world leader in technologies and services for life science R&D and manufacturing. Built upon its solid DNA synthesis technology, the company comprises four major business units: a life science services and products business unit, a biologics contract development and manufacturing organization (CDMO), an industrial synthetic products business unit, and an integrated global cell therapy company. GenScript accelerates scientific discovery and therapeutic breakthroughs for its customers. Since its founding in New Jersey, USA in 2002, GenScript has expanded its operations to serve more than 200,000 customers across 100 countries with a dedicated team of 6,900 employees. As of December 31, 2023, GenScript's services and products have been cited by 87,700 peer-reviewed journal articles worldwide. Guided by its mission to make people and nature healthier through biotechnology, GenScript strives to become the most trustworthy biotech company in the world.

Media Contacts
Kay Chuang
Head of Marketing, GenScript
[email protected]

SOURCE GenScript Biotech Corporation